New combo therapy aims to beat Cancer-Related insomnia

NCT ID NCT01628029

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining cognitive behavioral therapy, a stimulant (methylphenidate), melatonin, and light therapy can improve sleep in cancer patients. About 68 patients currently on cancer treatment who have sleep problems will participate. The study measures changes in sleep quality and fatigue over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Methylphenidate hydrochloride, melatonin, cognitive behavioral therapy, and light therapy
What this could lead to
If successful, this could provide a practical, multi-pronged approach to help cancer patients sleep better and feel less fatigued.
What could go wrong
This is a small, early-phase trial with only 68 participants, so results may not apply to everyone. The combination of treatments may cause side effects or not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.